- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
- AbCellera Announces Resignation of Board Member
- AbCellera to Present at Upcoming Investor Conferences in March
- AbCellera Reports Full Year 2023 Business Results
More ▼
Key statistics
On Wednesday, Abcellera Biologics Inc (ABCL:NSQ) closed at 3.78, 4.42% above its 52-week low of 3.62, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.77 |
---|---|
High | 3.96 |
Low | 3.66 |
Bid | 3.75 |
Offer | 3.97 |
Previous close | 3.78 |
Average volume | 1.36m |
---|---|
Shares outstanding | 292.78m |
Free float | 210.50m |
P/E (TTM) | -- |
Market cap | 1.11bn USD |
EPS (TTM) | -0.5062 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼